890 related articles for article (PubMed ID: 20197554)
1. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
4. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
5. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.
Sittig SP; van Beek JJP; Flórez-Grau G; Weiden J; Buschow SI; van der Net MC; van Slooten R; Verbeek MM; Geurtz PBH; Textor J; Figdor CG; de Vries IJM; Schreibelt G
Eur J Immunol; 2021 Jun; 51(6):1494-1504. PubMed ID: 33675038
[TBL] [Abstract][Full Text] [Related]
6. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
7.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
[TBL] [Abstract][Full Text] [Related]
10. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
11. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
12. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.
Hwu P; Du MX; Lapointe R; Do M; Taylor MW; Young HA
J Immunol; 2000 Apr; 164(7):3596-9. PubMed ID: 10725715
[TBL] [Abstract][Full Text] [Related]
14. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
Mellor AL; Chandler P; Baban B; Hansen AM; Marshall B; Pihkala J; Waldmann H; Cobbold S; Adams E; Munn DH
Int Immunol; 2004 Oct; 16(10):1391-401. PubMed ID: 15351783
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase.
Funeshima N; Fujino M; Kitazawa Y; Hara Y; Hara Y; Hayakawa K; Okuyama T; Kimura H; Li XK
J Gene Med; 2005 May; 7(5):565-75. PubMed ID: 15543532
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
17. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
18. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
20. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
